Quang Pham Sells Shares of CVKD
CVKD's Chairman, CEO, and Interim CFO, Quang Pham, sold shares on June 12, 2026.
Key Points
- Quang Pham, CVKD's Chairman, CEO, and Interim CFO, sold 12,996 shares on June 12, 2026, at an average price of $3.94, totaling $51,204.24.
- Shares of CVKD traded near $3.33, with insider activity reflecting multiple sales in early June 2026.
- Institutional investors like Vanguard and BlackRock have made notable changes to their CVKD positions recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Quang Pham, who serves as the Chairman, CEO, and Interim CFO of CVKD, recently sold 12,996 shares of the company on June 12, 2026. The shares were sold at an average price of $3.94, amounting to a total transaction value of $51,204.24. This sale is part of a series of insider transactions by Pham in June 2026.
Insider Buying and Selling at Cadrenal Therapeutics, Inc.
Quang Pham has been actively selling shares of CVKD throughout June 2026. On June 15, he sold 3,666 shares at an average price of $3.58. Earlier, on June 11, he sold 1,462 shares for $4.12 each. On June 10, a planned sale involved 3,500 shares at $4.21. Additionally, on June 9, he sold 12,992 shares at $4.06, and on June 8, another planned sale involved 5,893 shares at $4.38.
Other Institutional Activity in CVKD
Vanguard Capital Management LLC recently increased its holdings in CVKD by 45,201 shares, bringing its total to 45,201 shares valued at about $231,429. Geode Capital Management, LLC added 7,098 shares, now holding 21,626 shares worth $110,724. Vanguard Fiduciary Trust Co acquired 8,311 shares, totaling 8,311 shares valued at $42,552. BlackRock, Inc. also increased its position by 1,974 shares, now holding 5,496 shares valued at $28,140.
Cadrenal Therapeutics, Inc. Stock Up 116.2%
Shares of CVKD are trading near $3.33. Despite recent insider activity, the stock's performance continues to be closely monitored by investors. The company's market performance and valuation metrics remain a point of interest for both institutional and individual investors.
$CVKD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On April 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on CVKD with a price target of $13.0. This follows previous ratings from the firm, which reiterated a 'buy' rating with a $32.0 target on May 16, 2025. Noble Financial also maintained a 'buy' rating with a $4.0 target on March 13, 2024.
Bottom Line
Quang Pham's recent sales of CVKD shares are part of a broader pattern of insider activity in early June 2026. Investors often keep an eye on such transactions for potential insights into company leadership's confidence in the stock. Meanwhile, institutional investors have been adjusting their positions, and analysts continue to express a positive outlook with maintained 'buy' ratings and varied price targets. As always, these insights are based on past activities and do not necessarily predict future performance.
Get Cadrenal Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CVKD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.